Pharma & Biotech - Page 25

Viatris has received a formal rebuke from the US Food and Drug Administration over a direct-to-consumer video that allegedly misled viewers about the use of a cystic fibrosis inhaler. The FDA sent

Eli Lilly and contract manufacturer Resilience have committed $750 million to significantly expand production of Lilly’s KwikPen injectable device across its diabetes and obesity medicine portfolio. The investment will fund major upgrades

Four Democratic senators are demanding answers from Health and Human Services Secretary Robert F. Kennedy Jr. over potential conflicts of interest tied to a recent Merck settlement. Merck & Co. (MRK) agreed

Amgen (AMGN) has teamed up with YouTube megastar MrBeast to raise awareness and funding for pediatric cancer research through a high-profile video campaign. The collaboration was featured in MrBeast’s video titled “I

Sanofi (SNY) chief executive Belén Garijo has used her first earnings call as CEO to lay out an ambitious vision for reversing the French pharmaceutical giant’s recent fortunes. Garijo, who previously led

Chip Parkinson, CEO of Gifthealth, says specialty medicine represents the clearest opportunity for direct-to-patient models to prove their value at scale. Specialty drugs already account for more than half of all drug

Legend Biotech has confirmed that chief executive Ying Huang, Ph.D., has stepped down after six years leading the company. Alan Bash, who has served as president of Carvykti since 2024, will take

Novo Nordisk has filed a lawsuit against rival Eli Lilly (LLY), accusing the US drugmaker of running “false and misleading” advertisements for its obesity drug Zepbound. The legal clash between two of

Pharmaceutical supply chains face mounting pressure to maintain precise product traceability at every stage of the distribution process. Aggregation, the process of linking serialised items to their parent containers, has emerged as

Karyopharm Therapeutics has suffered a severe blow after its flagship drug selinexor, sold as Xpovio, failed to meet its primary endpoint in a Phase 3 endometrial cancer trial. The XPORT-EC-042 trial evaluated